Structure Therapeutics Inc. Sponsored ADR $GPCR Stake Lessened by Federated Hermes Inc.

Federated Hermes Inc. lessened its holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 99.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,500 shares of the company’s stock after selling 463,800 shares during the period. Federated Hermes Inc.’s holdings in Structure Therapeutics were worth $126,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Universal Beteiligungs und Servicegesellschaft mbH lifted its stake in Structure Therapeutics by 31.9% in the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 15,714 shares of the company’s stock worth $440,000 after acquiring an additional 3,800 shares in the last quarter. Pacific Heights Asset Management LLC lifted its position in shares of Structure Therapeutics by 52.2% in the third quarter. Pacific Heights Asset Management LLC now owns 700,000 shares of the company’s stock worth $19,600,000 after purchasing an additional 240,000 shares in the last quarter. Janney Capital Management LLC acquired a new stake in shares of Structure Therapeutics during the third quarter worth approximately $384,000. SG Americas Securities LLC grew its position in Structure Therapeutics by 106.4% during the third quarter. SG Americas Securities LLC now owns 39,700 shares of the company’s stock valued at $1,112,000 after purchasing an additional 20,461 shares in the last quarter. Finally, Osaic Holdings Inc. grew its position in Structure Therapeutics by 101.9% during the second quarter. Osaic Holdings Inc. now owns 63,362 shares of the company’s stock valued at $1,314,000 after purchasing an additional 31,972 shares in the last quarter. 91.78% of the stock is owned by institutional investors and hedge funds.

Structure Therapeutics Price Performance

Shares of NASDAQ:GPCR opened at $78.93 on Tuesday. The stock has a market capitalization of $4.79 billion, a P/E ratio of -64.70 and a beta of -2.07. The business has a 50-day moving average of $71.70 and a two-hundred day moving average of $41.82. Structure Therapeutics Inc. Sponsored ADR has a fifty-two week low of $13.22 and a fifty-two week high of $94.90.

Wall Street Analyst Weigh In

GPCR has been the subject of a number of research reports. Zacks Research lowered shares of Structure Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Friday, October 17th. Wall Street Zen lowered Structure Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 31st. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Thursday, January 22nd. The Goldman Sachs Group raised Structure Therapeutics to a “strong-buy” rating in a research note on Tuesday, January 20th. Finally, Citizens Jmp boosted their price target on Structure Therapeutics from $87.00 to $120.00 and gave the company a “market outperform” rating in a research note on Friday, December 12th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Structure Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $104.45.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.